ODN 1585|cas:386832-46-8|西域试剂

ODN 1585,93.90%

产品编号：Bellancom-150725| CAS NO：386832-46-8| 分子量：6430.00

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-150725		￥5200.00	杭州北京（现货）
Bellancom-150725		￥11500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ODN 1585

产品介绍

ODN 1585 是一种有效的 IFN 和TNFα 产生诱导剂。ODN 1585 是一种有效的 NK (自然杀手)刺激剂。ODN 1585 增加 CD8+ T 细胞的功能，包括 CD8+ T 细胞介导的 IFN-γ 的产生。ODN 1585诱导小鼠已建立的黑色素瘤消退。ODN 1585 对小鼠的疟疾具有完全的保护作用。ODN 1585 可用于急性骨髓性白血病 (AML) 和疟疾研究。ODN 1585 可作为疫苗佐剂。

生物活性

ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant.

体外研究

ODN 1585 (3 μg/mL, 48 h) induces PBMC producing IFN-α in the nanogram range.
ODN 1585 increases the percentage of CD69+ (early marker of activation) NK cells within 24 h (26±7%).
CpG ODN (0.6μg/mL, 18 h) stimulates NK cell-mediated lysis of K562 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ODN 1585 (50-500 μg, Injection into the tibialis anterior muscle, single) protects 20 to 90% of mice from sporozoite infection.
ODN 1585 (100 μg/dose, IP, twice weekly) is determined to be optimal for the induction of antitumor responses in several systems involving comparisons of 30, 100, and 300 μg/injection.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c ByJ mice (4- to 8-week-old, female, 6-18 mice in each group)
Dosage:	50, 100, 200, or 500 μg (in 50 μL of saline)
Administration:	Injection into the tibialis anterior muscle, single (at 7, 2, or 1 day(s) prior to sporozoite infection, on the day of infection, and/or at 1 day postinfection)
Result:	Protected 20 to 90% of mice from infection when the ODN 1585 was administered around the time of sporozoite challenge with doses of 50 to 500 μg. The highest level of protection (90%) resulted from administration of 200 μg of CpG ODN 1585 the day before challenge or 100 μg of CpG ODN 1585 on the day before and the day of challenge.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c ByJ mice (4- to 8-week-old, female, 6-18 mice in each group)
Dosage:	50, 100, 200, or 500 μg (in 50 μL of saline)
Administration:	Injection into the tibialis anterior muscle, single (at 7, 2, or 1 day(s) prior to sporozoite infection, on the day of infection, and/or at 1 day postinfection)
Result:	Protected 20 to 90% of mice from infection when the ODN 1585 was administered around the time of sporozoite challenge with doses of 50 to 500 μg. The highest level of protection (90%) resulted from administration of 200 μg of CpG ODN 1585 the day before challenge or 100 μg of CpG ODN 1585 on the day before and the day of challenge.

性状

Solid

溶解性数据

In Vitro:

H₂O : 20 mg/mL (3.11 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.1555 mL	0.7776 mL	1.5552 mL
5 mM	---	---	---
10 mM	---	---	---

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献